Company intelligence / Profile preview
Modulation Therapeutics
Florida, United Statesseed.nih.gov ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Modulation Therapeutics is a clinical-stage company developing novel therapeutics for cancer and liver diseases. Its lead molecule, MTI‑201, is in Phase I clinical trials for uveal melanoma. Other programs are in preclinical development targeting kidney neoplasms, multiple myeloma, and other cancers. The company is also advancing a potent SCD1 inhibitor for hepatocellular carcinoma and NASH.[1][3]
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small molecule drugsSynthetic peptidesPeptide conjugate radionuclidesDiagnostic radiopharmaceuticals[3]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Modulation Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Modulation Therapeutics.